Previous Close | 200.84 |
Open | 198.27 |
Bid | 177.05 x 100 |
Ask | 210.00 x 100 |
Day's Range | 195.81 - 198.66 |
52 Week Range | 146.09 - 207.14 |
Volume | 278,868 |
Avg. Volume | 546,550 |
Market Cap | 17.129B |
Beta | 0.64 |
PE Ratio (TTM) | 66.92 |
EPS (TTM) | 2.94 |
Earnings Date | May 4, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 200.86 |
WESTBROOK, Maine, April 12, 2018 /PRNewswire/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2018 first quarter financial results for Friday, May 4 before the market opens. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. To listen to the live conference call, please dial 1-800-288-8967 or 1-612-234-9960 and reference confirmation code 447373.
IDEXX Laboratories Inc at Raymond James Institutional Investors Conference
The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, IDEXX Laboratories, Kohl's and Motorola Solutions
We have highlighted five S&P 500 stocks that have dished out double-digit returns in Q1 and remained undisturbed by higher bouts of volatility
This could indicate that investors who seek to profit from falling equity prices are not currently targeting IDXX. Over the last one-month, outflows of investor capital in ETFs holding IDXX totaled $3.36 billion.
IDEXX (IDXX) might gain from the commercial launch of Catalyst SDMA Test in North America. As a result, its point-of-care customers can add SDMA as an essential element to the routine chemistry panel.
Idexx Laboratories Inc NASDAQ/NGS:IDXX
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting IDXX. Over the last one-month, outflows of investor capital in ETFs holding IDXX totaled $16.34 billion.
IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.
Idexx Laboratories Inc NASDAQ/NGS:IDXX
IDEXX Laboratories Inc (NASDAQ:IDXX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
WESTBROOK, Maine , Feb. 15, 2018 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate ...
Idexx Laboratories Inc NASDAQ/NGS:IDXX
Q4 2017 IDEXX Laboratories Inc Earnings Call
Chairman, President & CEO of Idexx Laboratories Inc (NASDAQ:IDXX) Jonathan W Ayers sold 36,000 shares of IDXX on 02/06/2018 at an average price of $179.28 a share.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.
Second Sight (EYES) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.
The animal-testing company is growing faster than its customers.
IDEXX Advances Power of SediVue Dx with Latest Software Update
Neural Network 3.0 Brings Machine Learning, 70 Million Images into the Veterinary Practice for Faster, More Accurate Urine Sediment Analysis WESTBROOK, Maine , Feb. 5, 2018 /PRNewswire/ -- IDEXX Laboratories, ...
Jim Cramer flies through his take on callers' favorite stocks, including a drug play he owns for his charitable trust.
Jim Cramer predicts that shares of Boeing, Mastercard, Idexx Laboratories and Nvidia could all hit lofty price targets in the near future.